Hims & Hers Health, Inc. HIMS
Launched in 2017, Hims & Hers Health, Inc. (and together with its subsidiaries, "Hims & Hers", the "Company", "we", "us" or "our") has built a consumer-first platform transforming the way customers fulfill their health and wellness needs. We believe that the Company has the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format. The Hims & Hers platforms (collectively, our "platform") include access to a highly-qualified and technologically-innovative provider network, an electronic medical record system designed to support providers and customers, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Our digital platform enables access to treatments for a broad range of chronic conditions, including those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate, including through personalized treatment plans, with prescriptions fulfilled online through licensed pharmacies. In addition, we also offer access to a range of non-prescription health and wellness products. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Since our founding, we have facilitated over fifty million telehealth consultations, enabling greater access to high-quality, convenient, affordable, personalized care for people in the United States, Canada, the United Kingdom, and the European Union (in Germany, the Republic of Ireland, France, and Spain).
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.35B | $1.48B | $872.0M | $526.9M | $271.9M | $148.8M | $82.6M | — |
| Cost of revenue | $614.3M | $303.4M | $157.1M | $118.2M | $67.4M | $39.3M | $38.0M | — |
| Gross profit | $1.73B | $1.17B | $714.9M | $408.7M | $204.5M | $109.5M | $44.6M | — |
| SG&A | $272.7M | $167.8M | $129.9M | $98.2M | $113.7M | $26.0M | $55.9M | — |
| Total operating expenses | $1.63B | $1.11B | $744.4M | $477.4M | $319.5M | $124.6M | $119.0M | — |
| Operating income | $105.6M | $61.9M | -$29.5M | -$68.7M | -$115.0M | -$15.1M | -$74.4M | — |
| Interest expense | — | — | — | — | $0 | $10.0K | $369.0K | — |
| Pre-tax income | $123.9M | $71.7M | -$21.6M | -$65.7M | -$110.8M | -$18.0M | -$72.0M | — |
| Income tax | $4.4M | $54.3M | $2.0M | $31.0K | $3.1M | $127.0K | $90.0K | — |
| Net income | $128.4M | $126.0M | -$23.5M | -$65.7M | -$107.7M | -$18.1M | -$72.1M | — |
| EPS, basic | 0.57 | 0.58 | -0.11 | -0.32 | -0.58 | -0.51 | -2.07 | — |
| EPS, diluted | 0.51 | 0.53 | -0.11 | -0.32 | -0.58 | -0.51 | -2.07 | — |
| Shares, diluted (wtd. avg.) | 258.2M | 236.8M | 209.3M | 204.5M | 186.8M | 35.4M | 34.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $228.6M | $220.6M | $96.7M | $47.6M | $72.6M | $28.4M | $22.8M | $41.6M |
| Short-term investments | $348.9M | $79.7M | $124.3M | $132.9M | $175.5M | $72.9M | — | — |
| Receivables | $32.1M | $6.1M | $6.7M | $3.9M | $4.1M | $1.1M | — | — |
| Inventory | $80.1M | $64.4M | $22.5M | $21.6M | $13.6M | $3.5M | — | — |
| Total current assets | $767.6M | $395.8M | $265.1M | $216.6M | $269.9M | $113.1M | $1.7M | — |
| Property, plant and equipment | — | — | — | $3.0M | $2.2M | $1.7M | — | — |
| Goodwill | $278.3M | $112.7M | $110.9M | $110.9M | $110.9M | $0 | — | — |
| Other intangibles | $196.1M | $43.4M | $18.6M | $21.8M | $25.9M | $59.0K | — | — |
| Total assets | $2.15B | $707.5M | $441.2M | $366.3M | $420.6M | $118.7M | $204.8M | — |
| Accounts payable | $143.3M | $91.2M | $43.1M | $32.4M | $19.6M | $8.1M | $18.5K | — |
| Total current liabilities | $404.4M | $221.4M | $88.5M | $47.9M | $79.2M | $15.2M | $979.4K | — |
| Total liabilities | $1.61B | $230.8M | $97.2M | $54.6M | $86.0M | $15.6M | $8.2M | — |
| Retained earnings | -$113.8M | -$242.1M | -$368.2M | -$344.6M | -$279.0M | -$171.3M | $1.1M | — |
| Total equity | $540.9M | $476.7M | $344.0M | $311.7M | $334.6M | -$146.9M | -$139.8M | -$71.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $300.0M | $251.1M | $73.5M | -$26.5M | -$34.4M | -$2.5M | -$74.9M | — |
| Depreciation and amortisation | $54.5M | $17.1M | $9.5M | $7.5M | $4.1M | $1.1M | $260.0K | — |
| Stock-based compensation | $135.2M | $92.3M | $66.1M | $42.8M | $67.2M | $5.8M | $8.0M | — |
| Capital expenditure | $242.6M | $52.8M | $26.5M | $7.2M | — | — | — | — |
| Investing cash flow | -$1.02B | -$19.0M | -$12.1M | $34.7M | -$156.3M | -$39.7M | -$39.3M | — |
| Financing cash flow | $729.6M | -$107.8M | -$11.5M | -$33.1M | $235.0M | $47.7M | $95.3M | — |
| Buybacks | $90.0M | $83.0M | $2.0M | $0 | $0 | $0 | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001773751-26-000060.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $82.6M | $148.8M | $271.9M | $526.9M | $872.0M | $1.48B | $2.35B |
| Gross profit | — | $44.6M | $109.5M | $204.5M | $408.7M | $714.9M | $1.17B | $1.73B |
| Net income | — | -$72.1M | -$18.1M | -$107.7M | -$65.7M | -$23.5M | $126.0M | $128.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- New debt or obligation Item 2.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- New debt or obligation Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8011
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| TDOC | Teladoc Health, Inc. | $1.15B | — | -1.5% |
| STLN | Starling Oncology, Inc. | $683.9M | — | 27.8% |
| SBC | SBC Medical Group Holdings Inc | $543.0M | 10.6x | -15.5% |
| LFMD | LifeMD, Inc. | $102.7M | 8.5x | 25.3% |
| AIRS | Airsculpt Technologies, Inc. | $86.5M | — | -15.8% |
| CCM | Concord Medical Services Holdings Ltd | — | — | 26.6% |
| BMGL | Basel Medical Group Ltd | — | — | — |